Last reviewed · How we verify
NCT04159129
Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
trial in Pulmonary Disease, Chronic Obstructive in 43 participants. Status unknown.
30 April 2020
Quick facts
| Lead sponsor | Schön Klinik Berchtesgadener Land |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 43 |
| Start date | 7 November 2019 |
| Primary completion | 30 April 2020 |
| Estimated completion | 31 July 2020 |
| Sites | 1 location across Germany |
Conditions studied
- Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →
- Lung Diseases, Interstitial — all drugs for Lung Diseases, Interstitial →
Sponsor
Schön Klinik Berchtesgadener Land
Who can join
Adults 40 to 85, any sex, with Pulmonary Disease, Chronic Obstructive or Lung Diseases, Interstitial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the effects of a three-week inpatient pulmonary rehabilitation (PR) program on the walking speed in patients with chronic obstructive (COPD) or interstitial lung disease (ILD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04159129
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Disease, Chronic Obstructive
Currently open trials in the same condition.
- NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
- NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting
Other Schön Klinik Berchtesgadener Land trials
Trials by the same sponsor.
- NCT07013903 — Effects of Hydrotherapy During Post-COVID-19 Rehabilitation · NA · recruiting
- NCT06545851 — Effects of an Automatic Oxygen Titration System in People With Hypoxemia During Exercise Training · NA · recruiting
- NCT05172206 — Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial · NA · completed
- NCT05124548 — Sleep Characteristics in Post-COVID-19 Patients · completed
- NCT05126511 — Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04159129 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Schön Klinik Berchtesgadener Land
- Last refreshed: 22 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04159129.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing